Overview

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Olodaterol
Tiotropium Bromide